Patents-Review.com
🔗 Permalink
Assignee profile:

AGENEBIO, INC.

City:

Baltimore, Maryland

Country:

United States

Published Applications:

15

Last publication date:

2023-05-04

Patent Grants:

15

Last grant date:

2026-01-20

Top Inventors for applications by AGENEBIO, INC.

These are the the leading inventors for applications assigned to AGENEBIO, INC.:

Recent patent applications by AGENEBIO, INC.

AGENEBIO, INC. based in Baltimore, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-05-04 ✅ Patent 12,528,819 granted on 2026-01-20
US20230134844A1
Chemistry; metallurgy

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

 #2 | 2023-04-06 ✅ Patent 12,291,535 granted on 2025-05-06
US20230107032A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #3 | 2022-09-01 ✅ Patent 12,024,525 granted on 2024-07-02
US20220274996A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #4 | 2021-08-19 ✅ Patent 11,505,555 granted on 2022-11-22
US20210253588A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #5 | 2021-01-14 ✅ Patent 11,312,721 granted on 2022-04-26
US20210009602A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #6 | 2020-02-13 ✅ Patent 11,414,425 granted on 2022-08-16
US20200048268A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #7 | 2019-09-19 ✅ Patent 11,142,529 granted on 2021-10-12
US20190284196A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #8 | 2019-02-21 ✅ Patent 10,815,242 granted on 2020-10-27
US20190055258A1
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #9 | 2018-05-24 ✅ Patent 10,925,834 granted on 2021-02-23
US20180140555A1
Human necessities

Extended release pharmaceutical compositions of levetiracetam

 #10 | 2017-09-07 ✅ Patent 10,329,301 granted on 2019-06-25
US20170253603A2
Chemistry; metallurgy

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

 #11 | 2017-04-20 ✅ Patent 10,159,648 granted on 2018-12-25
US20170105939A1
Human necessities

Extended release pharmaceutical compositions of levetiracetam

 #12 | 2017-01-26 ✅ Patent 10,329,301 granted on 2019-06-25
US20170022208A1
Chemistry; metallurgy

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

 #13 | 2016-09-22 ✅ Patent 11,160,785 granted on 2021-11-02
US20160271108A1
Human necessities

Methods and compositions for improving cognitive function

 #14 | 2016-01-14 ✅ Patent 9,801,879 granted on 2017-10-31
US20160008357A1
Human necessities

Pyridazine derivatives, compositions and methods for treating cognitive impairment

 #15 | 2013-09-12 ✅ Patent 9,145,372 granted on 2015-09-29
US20130237545A1
Chemistry; metallurgy

Pyridazine derivatives, compositions and methods for treating cognitive impairment

Also check out AGENEBIO, INC.'s (Baltimore, United States) applicant profile with 17 patent applications submitted.

AssigneeID:

126325 ⎘